Discover
SMMT
Summit Therapeutics Inc.
14.38
2 x 13.34
2 x 15.47
bid
ask
-
0.19
1.30%
2 @ 04:00 PM
14.65 +0.27 (1.88%)
| Ytd | -17.78% | |
| 1y | -32.17% |
14.30
day range
14.80
12.55
52 week range
30.98
| Open | 14.59 | Prev Close | 14.57 | Low | 14.30 | High | 14.80 | Mkt Cap | 11.16B |
| Vol | 3.84M | Avg Vol | 5.34M | EPS | -1.59 | P/E | N/A | Forward P/E | -12.53 |
| Beta | -1.31 | Short Ratio | 5.67 | Inst. Own | 15.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 16.86 | 200-d Avg | 17.70 | 1yr Est | 28.39 |
| Income Statement | |||
| Operating Expenses | 195.21M | ||
| Research and Development Expense | 132.62M | ||
| Selling, General and Administrative Expense | 62.59M | ||
| Operating Income | -195.21M | ||
| Net Income | -189.42M | ||
| Net Income Common Stock | -189.42M | ||
| Net Income Common Stock (USD) | -189.42M | ||
| Consolidated Income | -189.42M | ||
| Earnings per Basic Share | 0.00 | ||
| Earnings per Basic Share (USD) | 0.00 | ||
| Earnings per Diluted Share | 0.00 | ||
| Earning Before Interest & Taxes (EBIT) | -189.42M | ||
| Earning Before Interest & Taxes (USD) | -189.42M | ||
| Weighted Average Shares | 775.46M | ||
| Weighted Average Shares Diluted | 775.46M | ||
| Balance Sheet | |||
| Cash and Equivalents | 106.83M | ||
| Cash and Equivalents (USD) | 106.83M | ||
| Investments | 492.22M | ||
| Investments Current | 492.22M | ||
| Current Assets | 616.60M | ||
| Property, Plant & Equipment Net | 21.06M | ||
| Total Assets | 647.86M | ||
| Debt Current | 3.18M | ||
| Total Debt | 20.04M | ||
| Current Liabilities | 83.27M | ||
| Debt Non-Current | 16.86M | ||
| Total Liabilities | 101.92M | ||
| Accumulated Retained Earnings (Deficit) | -2.48B | ||
| Accumulated Other Comprehensive Income | -2.63M | ||
| Shareholders Equity | 545.93M | ||
| Shareholders Equity (USD) | 545.93M | ||
| Assets Non-Current | 31.26M | ||
| Total Debt (USD) | 20.04M | ||
| Goodwill and Intangible Assets | 1.97M | ||
| Liabilities Non-Current | 18.66M | ||
| Trade and Non-Trade Payables | 27.55M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 44.00K | ||
| Net Cash Flow from Financing | 3.80M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -118.75M | ||
| Capital Expenditure | -245.00K | ||
| Issuance (Purchase) of Equity Shares | 3.80M | ||
| Net Cash Flow from Investing | -238.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 7.00K | ||
| Net Cash Flow from Operations | -122.29M | ||
| Effect of Exchange Rate Changes on Cash | -19.00K | ||
| Share Based Compensation | 72.79M | ||